Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other financing activities (2018 - 2024)

Capricor Therapeutics has reported Other financing activities over the past 9 years, most recently at $2.3 million for Q4 2024.

  • Quarterly results put Other financing activities at $2.3 million for Q4 2024, up 23.31% from a year ago — trailing twelve months through Dec 2024 was $9.8 million (up 32.1% YoY), and the annual figure for FY2024 was $9.8 million, up 32.1%.
  • Other financing activities for Q4 2024 was $2.3 million at Capricor Therapeutics, up from $2.1 million in the prior quarter.
  • Over the last five years, Other financing activities for CAPR hit a ceiling of $3.3 million in Q1 2024 and a floor of $287807.0 in Q1 2020.
  • Median Other financing activities over the past 5 years was $1.1 million (2022), compared with a mean of $1.3 million.
  • Biggest five-year swings in Other financing activities: surged 467.03% in 2020 and later rose 1.13% in 2021.
  • Capricor Therapeutics' Other financing activities stood at $473745.0 in 2020, then skyrocketed by 64.68% to $780150.0 in 2021, then skyrocketed by 47.18% to $1.1 million in 2022, then surged by 62.14% to $1.9 million in 2023, then grew by 23.31% to $2.3 million in 2024.
  • The last three reported values for Other financing activities were $2.3 million (Q4 2024), $2.1 million (Q3 2024), and $2.2 million (Q2 2024) per Business Quant data.